A high-level overview of BioGaia AB (publ) (BIOGY) stock. View (BIOGY) real-time stock price, chart, news, analysis, analyst reviews and more.

Complete BioGaia AB Series B stock information by Barron's. View real-time BGLA stock price and news, along with industry-best analysis.

Reuteri tablets were also launched in Hong Kong this month, by J Health Enterprise. On the packaging side, however, BioGaia suffered a setback in the quarter as adjustments to its patented bottlecap ...

BioGaia has signed an exclusive distributor agreement with Phillips Pharma Group for the rights to sell BioGaia ProTectis drops, tablets and Oral Rehydration Solution in Kenya, Nigeria and Ghana.

BioGaia offers a high dividend yield of 6.81%, ranking in the top 25% of Swedish dividend payers, but its sustainability is questionable due to an elevated cash payout ratio of 191.2%.

BioGaia's recent earnings show a robust increase, with Q2 sales up to SEK 384.12 million and net income at SEK 111.01 million. Despite a healthy payout ratio of 47.8%, indicating earnings cover ...

BioGaia reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and strategic ...

2016-05-26 Rights issue in IBT fully subscribed – BioGaia’s underwriting guarantee will not be utilized 2016-05-17 BioGaia’s probiotic effective in treating abdominal pain in children ...

EQT Public Value to invest in BioGaia through participation in a directed issue As an active and long-term owner, EQT Public Value intends to work closely with existing shareholders, the board of ...

Oct 25 (Reuters) - Biogaia Ab. Oct 25 (Reuters) - Biogaia Ab. Skip to main content. Exclusive news, data and analytics for financial market professionals Learn more about Refinitiv. Reuters home.

BioGaia's total investment in IBT thus amounts to approximately SEK 82 million and its holding to 94.5 per cent. Efforts to evaluate the possibility for a separate listing of IBT are continuing.